Quinolones in 2005: An update

Clinical Microbiology and Infection

Volumn 11, Issue 4, 2005, Pages 256-280

  Van Bambeke, F ^a   Michot, J M ^a   Van Eldere, J ^b   Tulkens, P M ^a  

^a UNIVERSITÉ CATHOLIQUE DE LOUVAIN   (Belgium)

^b REGA INSTITUTE FOR MEDICAL RESEARCH   (Belgium)

Author keywords

Ciprofloxacin; Pharmacodynamics; Quinolones; Resistance; Review; Toxicity

Indexed keywords

AMINOGLYCOSIDE ANTIBIOTIC AGENT; ANTIINFECTIVE AGENT; BETA LACTAM ANTIBIOTIC; CHLORAMPHENICOL; CIPROFLOXACIN; CLINAFLOXACIN; ENOXACIN; FLEROXACIN; FLUMEQUINE; GARENOXACIN; GATIFLOXACIN; GEMIFLOXACIN; GREPAFLOXACIN; LEVOFLOXACIN; LOMEFLOXACIN; MACROLIDE; MOXIFLOXACIN; NALIDIXIC ACID; NORFLOXACIN; OFLOXACIN; PEFLOXACIN; PENICILLIN G; QUINOLINE DERIVED ANTIINFECTIVE AGENT; RIFAMPICIN; SPARFLOXACIN; SULFONAMIDE; TEMAFLOXACIN; TRIMETHOPRIM; TROVAFLOXACIN; UNINDEXED DRUG;

ABNORMALLY HIGH SUBSTRATE CONCENTRATION IN BLOOD; AMINOTRANSFERASE BLOOD LEVEL; ANTIBACTERIAL ACTIVITY; ANTIBIOTIC RESISTANCE; AREA UNDER THE CURVE; ARTHRALGIA; BACTERIAL INFECTION; CARDIOTOXICITY; CARDIOVASCULAR SYMPTOM; CENTRAL NERVOUS SYSTEM DISEASE; CLONAL VARIATION; COMMUNITY ACQUIRED PNEUMONIA; CONFUSION; DIARRHEA; DIZZINESS; DRUG ADMINISTRATION ROUTE; DRUG BIOAVAILABILITY; DRUG COST; DRUG EFFICACY; DRUG INDICATION; DRUG MECHANISM; DRUG PENETRATION; DRUG POTENCY; DRUG STRUCTURE; EUROPE; GASTROINTESTINAL SYMPTOM; GENE MUTATION; GENOTOXICITY; HEMATOLOGIC DISEASE; HUMAN; HYPOGLYCEMIA; INSOMNIA; KIDNEY FAILURE; LIVER DISEASE; LIVER TOXICITY; MENINGITIS; MINIMUM INHIBITORY CONCENTRATION; NAUSEA; NONHUMAN; PHARMACODYNAMICS; PHARMACOPHORE; PHOTOTOXICITY; PRIORITY JOURNAL; REVIEW; SKIN MANIFESTATION; STRUCTURE ACTIVITY RELATION; TENDINITIS; THOUGHT DISORDER; THROMBOCYTOPENIA; URINARY TRACT INFECTION; VOMITING;

EID: 15944382760     PISSN: 1198743X     EISSN: None     Source Type: Journal    
DOI: 10.1111/j.1469-0691.2005.01131.x     Document Type: Review

References (312)

1. Domagala JM. Structure-activity and structure-side-effect relationships for the quinolone antibacterials. J Antimicrob Chemother 1994; 33: 685-706.
2. Domagala JM, Hagen SE. Structure-activity relationships of the quinolone antibacterials in the new millenium: some things change and some do not. In: Hooper DC, Rubinstein E, eds. Quinolone antimicrobial agents. Washington, DC: ASM Press, 2003; 3-18.
3. Quale J, Landman D, Ravishankar J, Flores C, Bratu S. Streptococcus pneumoniae, Brooklyn, New York: fluoroquinolone resistance at our doorstep. Emerg Infect Dis 2002; 8: 594-597.
4. Ho PL. Decreased levofloxacin susceptibility in Haemophilus influenzae in children, Hong Kong. Emerg Infect Dis 2004; 10: 1960-1962.
5. Pallares R, Fenoll A, Linares J. The epidemiology of antibiotic resistance in Streptococcus pneumoniae and the clinical relevance of resistance to cephalosporins, macrolides and quinolones. Int J Antimicrob Agents 2003; 22(suppl 1): S15-S24.
6. Friedland I, Gallagher G, King T, Woods GL. Antimicrobial susceptibility patterns in Pseudomonas aeruginosa: data from a multicenter Intensive Care Unit Surveillance Study (ISS) in the United States. J Chemother 2004; 16: 437-441.
7. Blandino G, Marchese A, Ardito F et al. Antimicrobial susceptibility profiles of Pseudomonas aeruginosa and Staphylococcus aureus isolated in Italy from patients with hospital-acquired infections. Int J Antimicrob Agents 2004; 24 515-518.
8. Sprandel KA, Rodvold KA. Safety and tolerability of fluoroquinolones. Clin Cornerstone Suppl 2003; 3: S29-S36.
9. Andersson MI, MacGowan AP. Development of the quinolones. J Antimicrob Chemother 2003; 51(suppl 1): 1-11.
10. Felmingham D. Comparative antimicrobial susceptibility of respiratory tract pathogens. Chemotherapy 2004; 50(suppl 1): 3-10.
11. Cunha BA. Empiric therapy of community-acquired pneumonia: guidelines for the perplexed? Chest 2004; 125: 1913-1919.
12. Jacobs MR. Fluoroquinolones as chemotherapeutics against mycobacterial infections. Curr Pharm Des 2004; 10: 3213-3220.
13. Blondeau JM, Missaghi B. Gemifloxacin: a new fluoroquinolone. Expert Opin Pharmacother 2004; 5: 1117-1152.
14. Blasi F, Tarsia P, Cosentini R, Cazzola M, Allegra L. Therapeutic potential of the new quinolones in the treatment of lower respiratory tract infections. Expert Opin Invest Drugs 2003; 12 1165-1177.
15. Hooper DC, Rubinstein E, eds. Quinolone antimicrobial agents. Washington, DC: ASM Press, 2003.
16. Schmidt J, Pollack CV. Antibiotic use in the emergency department. III. The quinolones, new beta lactams, beta lactam combination agents, and miscellaneous antibiotics. J Emerg Med 1996; 14: 483-496.
17. Grossman RF. The role of fluoroquinolones in respiratory tract infections. J Antimicrob Chemother 1997; 40(suppl A): 59-62.
18. Bakken JS. The fluoroquinolones: how long will their utility last? Scand J Infect Dis 2004; 36: 85-92.
19. Lode H, Allewelt M. Role of newer fluoroquinolones in lower respiratory tract infections. J Antimicrob Chemother 2002; 50 151-154.
20. Fish DN. Levofloxacin: update and perspectives on one of the original 'respiratory quinolones'. Expert Rev Anti Infect Ther 2003; 1: 371-387.
21. Ben David D, Rubinstein E. Appropriate use of antibiotics for respiratory infections: review of recent statements and position papers. Curr Opin Infect Dis 2002; 15: 151-156.
22. Lacombe K, Cariou S, Tilleul P, Offenstadt G, Meynard JL. Optimizing fluoroquinolone utilization in a public hospital: a prospective study of educational intervention. Eur J Clin Microbiol Infect Dis 2005; 24: 6-11.
23. Aubert G, Carricajo A, Vautrin AC et al. Impact of restricting fluoroquinolone prescription on bacterial resistance in an intensive care unit. J Hosp Infect 2005; 59: 83-89.
24. Cars O, Molstad S, Melander A. Variation in antibiotic use in the European Union. Lancet 2001; 357: 1851-1853.
25. Lesher GY, Foelich EJ, Gruett MD, Baily JH, Brundage PR. 1,8-Naphtyridine derivatives. A new class of chemotherapeutic agents. J Med Pharm Chem 1962; 91: 1063-1065.
26. Bhanot SK, Singh M, Chatterjee NR. The chemical and biological aspects of fluoroquinolones: reality and dreams. Curr Pharm Des 2001; 7: 311-335.
27. Ball P. Quinolone generations: natural history or natural selection? J Antimicrob Chemother 2000; 46(suppl T1): 17-24.
28. Shen LL, Pernet AG. Mechanism of inhibition of DNA gyrase by analogues of nalidixic acid: the target of the drugs is DNA. Proc Natl Acad Sci USA 1985; 82: 307-311.
29. Palu G, Valisena S, Ciarrocchi G, Gatto B, Palumbo M. Quinolone binding to DNA is mediated by magnesium ions. Proc Natl Acad Sci USA 1992; 89: 9671-9675.
30. Khodursky AB, Zechiedrich EL, Cozzarelli NR. Topoisomerase IV is a target of quinolones in Escherichia coli. Proc Natl Acad Sci USA 1995; 92: 11801-11805.
31. Morais Cabral JH, Jackson AP, Smith CV, Shikotra N, Maxwell A, Liddington RC. Crystal structure of the breakage-reunion domain of DNA gyrase. Nature 1997; 388: 903-906.
32. Drlica K. Control of bacterial DNA supercoiling. Mol Microbiol 1992; 6: 425-433.
33. Hooper DC. Fluoroquinolone resistance among Gram-positive cocci. Lancet Infect Dis 2002; 2: 530-538.
34. Wigley DB. Structure and mechanism of DNA topoisomerases. Ann Rev Biophys Biomol Struct 1995; 24: 185-208.
35. Drlica K, Zhao X. DNA gyrase, topoisomerase IV, and the 4-quinolones. Microbiol Mol Biol Rev 1997; 61: 377-392.
36. Alovero FL, Pan XS, Morris JE, Manzo RH, Fisher LM. Engineering the specificity of antibacterial fluoroquinolones: benzenesulfonamide modifications at C-7 of ciproftoxacin change its primary target in Streptococcus pneumoniae from topoisomerase IV to gyrase. Antimicrob Agents Chemother 2000; 44: 320-325.
37. Bryskier A, Chantot JF. Classification and structure-activity relationships of fluoroquinolones. Drugs 1995; 49(suppl 2): 16-28.
38. Peterson LR. Quinolone molecular structure-activity relationships: what we have learned about improving antimicrobial activity. Clin Infect Dis 2001; 33(suppl 3): S180-S186.
39. Pan XS, Fisher LM. DNA gyrase and topoisomerase IV are dual targets of clinafloxacin action in Streptococcus pneumoniae. Antimicrob Agents Chemother 1998; 42: 2810-2816.
40. Fukuda H, Kishii R, Takei M, Hosaka M. Contributions of the 8-methoxy group of gatifloxacin to resistance selectivity, target preference, and antibacterial activity against Streptococcus pneumoniae. Antimicrob Agents Chemother 2001; 45: 1649-1653.
41. Sanders CC. Mechanisms responsible for cross-resistance and dichotomous resistance among the quinolones. Clin Infect Dis 2001; 32(suppl 1): S1-S8.
42. Janoir C, Podglajen I, Kitzis MD, Poyart C, Gutmann L. In vitro exchange of fluoroquinolone resistance determinants between Streptococcus pneumoniae and viridans streptococci and genomic organization of the parE-parC region in S. mitis. J Infect Dis 1999; 180: 555-558.
43. Ferrandiz MJ, Fenoll A, Linares J, De La Campa AG. Horizontal transfer of parC and gyrA in fluoroquinolone-resistant clinical isolates of Streptococcus pneumoniae. Antimicrob Agents Chemother 2000; 44: 840-847.
44. Yoshida H, Bogaki M, Nakamura M, Nakamura S. Quinolone resistance-determining region in the DNA gyrase gyrA gene of Escherichia coli. Antimicrob Agents Chemother 1990; 34: 1271-1272.
45. Willmott CJ, Maxwell A. A single point mutation in the DNA gyrase A protein greatly reduces binding of fluoroquinolones to the gyrase-DNA complex. Antimicrob Agents Chemother 1993; 37: 126-127.
46. Hooper DC. Mechanisms of fluoroquinolone resistance. Drug Resist Update 1999; 2: 38-55.
47. Pan XS, Fisher LM. Targeting of DNA gyrase in Streptococcus pneumoniae by sparfloxacin: selective targeting of gyrase or topoisomerase IV by quinolones. Antimicrob Agents Chemother 1997; 41: 471-474.
48. Fukuda H, Hiramatsu K. Primary targets of fluoroquinolones in Streptococcus pneumoniae. Antimicrob Agents Chemother 1999; 43 410-412.
49. Oizumi N, Kawabata S, Hirao M et al. Relationship between mutations in the DNA gyrase and topoisomerase IV genes and nadifloxacin resistance in clinically isolated quinolone-resistant Staphylococcus aureus. J Infect Chemother 2001; 7: 191-194.
50. Rupp J, Gebert A, Solbach W, Maass M. Serine-to-asparagine substitution in the gyrA gene leads to quinolone resistance in moxifloxacin-exposed Chlamydia pneumoniae. Antimicrob Agents Chemother 2005; 49: 406-407.
51. Gillespie SH, Voelker LL, Dickens A. Evolutionary barriers to quinolone resistance in Streptococcus pneumoniae. Microb Drug Resist 2002; 8: 79-84.
52. Blanche F, Cameron B, Bernard FX et al. Differential behaviors of Staphylococcus aureus and Escherichia coli type II DNA topoisomerases. Antimicrob Agents Chemother 1996; 40: 2714-2720.
53. Nishino Y, Deguchi T, Yasuda M et al. Mutations in the gyrA and parC genes associated with fluoroquinolone resistance in clinical isolates of Citrobacter freundii. FEMS Microbiol Lett 1997; 154: 409-414.
54. Georgiou M, Munoz R, Roman F et al. Ciprofloxacin-resistant Haemophilus influenzae strains possess mutations in analogous positions of GyrA and ParC. Antimicrob Agents Chemother 1996; 40: 1741-1744.
55. Deplano A, Zekhnini A, Allali N, Couturier M, Struelens MJ. Association of mutations in grlA and gyrA topoisomerase genes with resistance to ciprofloxacin in epidemic and sporadic isolates of methicillin-resistant Staphylococcus aureus. Antimicrob Agents Chemother 1997; 41: 2023-2025.
56. Gootz TD, Zaniewski RP, Haskell SL, Kaczmarek FS, Maurice AE. Activities of trovafloxacin compared with those of other fluoroquinolones against purified topoisomerases and gyrA and grlA mutants of Staphylococcus aureus. Antimicrob Agents Chemother 1999; 43: 1845-1855.
57. Varon E, Janoir C, Kitzis MD, Gutmann L. ParC and GyrA may be interchangeable initial targets of some fluoroquinolones in Streptococcus pneumoniae. Antimicrob Agents Chemother 1999; 43: 302-306.
58. Tankovic J, Bachoual R, Ouabdesselam S, Boudjadja A, Soussy CJ. In-vitro activity of moxifloxacin against fluoroquinolone-resistant strains of aerobic gram-negative bacilli and Enterococcus faecalis. J Antimicrob Chemother 1999; 43(suppl B): 19-23.
59. Boswell FJ, Andrews JM, Jevons G, Wise R. Comparison of the in vitro activities of several new fluoroquinolones against respiratory pathogens and their abilities to select fluoroquinolone resistance. J Antimicrob Chemother 2002; 50: 495-502.
60. Dong Y, Xu C, Zhao X, Domagala J, Drlica K. Fluoroquinolone action against mycobacteria: effects of C-8 substituents on growth, survival, and resistance. Antimicrob Agents Chemother 1998; 42 2978-2984.
61. Dalhoff A. Comparative in vitro and in vivo activity of the C-8 methoxy quinolone moxifloxacin and the C-8 chlorine quinolone BAY y 3118. Clin Infect Dis 2001; 32(suppl 1): S16-S22.
62. Zhao X, Xu C, Domagala J, Drlica K. DNA topoisomerase targets of the fluoroquinolones: a strategy for avoiding bacterial resistance. Proc Natl Acad Sci USA 1997; 94: 13991-13996.
63. Hooper DC, Wolfson JS, Souza KS, Tung C, McHugh GL, Swartz MN. Genetic and biochemical characterization of norfloxacin resistance in Escherichia coli. Antimicrob Agents Chemother 1986; 29: 639-644.
64. Legakis NJ, Tzouvelekis LS, Makris A, Kotsifaki H. Outer membrane alterations in multiresistant mutants of Pseudomonas aeruginosa selected by ciprofloxacin. Antimicrob Agents Chemother 1989; 33: 124-127.
65. Nikaido H. Outer membrane barrier as a mechanism of antimicrobial resistance. Antimicrob Agents Chemother 1989; 33 1831-1836.
66. Van Bambeke F, Glupczynski Y, Plesiat P, Pechere JC, Tulkens PM. Antibiotic efflux pumps in prokaryotic cells: occurrence, impact on resistance and strategies for the future of antimicrobial therapy. J Antimicrob Chemother 2003; 51: 1055-1065.
67. Saier MH, Paulsen IT, Sliwinski MK, Pao SS, Skurray RA, Nikaido H. Evolutionary origins of multidrug and drug-specific efflux pumps in bacteria. FASEB J 1998; 12: 265-274.
68. Hsieh PC, Siegel SA, Rogers B, Davis D, Lewis K. Bacteria lacking a multidrug pump: a sensitive tool for drug discovery. Proc Natl Acad Sci USA 1998; 95: 6602-6606.
69. Alonso A, Martinez JL. Multiple antibiotic resistance in Stenotrophomonas maltophilia. Antimicrob Agents Chemother 1997; 41 1140-1142.
70. Ghosh AS, Ahamed J, Chauhan KK, Kundu M. Involvement of an efflux system in high-level fluoroquinolone resistance of Shigella dysenteriae. Biochem Biophys Res Commun 1998; 242: 54-56.
71. Zeller V, Janoir C, Kitzis MD, Gutmann L, Moreau NJ. Active efflux as a mechanism of resistance to ciprofloxacin in Streptococcus pneumoniae. Antimicrob Agents Chemother 1997; 41: 1973-1978.
72. Kaatz GW, Seo SM. Mechanisms of fluoroquinolone resistance in genetically related strains of Staphylococcus aureus. Antimicrob Agents Chemother 1997; 41: 2733-2737.
73. Lomovskaya O, Lee A, Hoshino K et al. Use of a genetic approach to evaluate the consequences of inhibition of efflux pumps in Pseudomonas aeruginosa. Antimicrob Agents Chemother 1999; 43: 1340-1346.
74. Beyer R, Pestova E, Millichap JJ, Stosor V, Noskin GA, Peterson LR. A convenient assay for estimating the possible involvement of efflux of fluoroquinolones by Streptococcus pneumoniae and Staphylococcus aureus: evidence for diminished moxifloxacin, sparfloxacin, and trovafloxacin efflux. Antimicrob Agents Chemother 2000; 44: 798-801.
75. Boswell FJ, Andrews JM, Wise R. Comparison of the in vitro activities of BMS-284756 and four fluoroquinolones against Streptococcus pneumoniae. J Antimicrob Chemother 2001; 48: 446-447.
76. Zhanel GG, Walkty A, Nichol K, Smith H, Noreddin A, Hoban DJ. Molecular characterization of fluoroquinolone resistant Streptococcus pneumoniae clinical isolates obtained from across Canada. Diagn Microbiol Infect Dis 2003; 45: 63-67.
77. Grohs P, Houssaye S, Aubert A, Gutmann L, Varon E. In vitro activities of garenoxacin (BMS-284756) against Streptococcus pneumoniae, viridans group streptococci, and Enterococcus faecalis compared to those of six other quinolones. Antimicrob Agents Chemother 2003; 47: 3542-3547.
78. Brenwald NP, Gill MJ, Wise R. Prevalence of a putative efflux mechanism among fluoroquinolone-resistant clinical isolates of Streptococcus pneumoniae. Antimicrob Agents Chemother 1998; 42: 2032-2035.
79. Gill MJ, Brenwald NP, Wise R. Identification of an efflux pump gene, pmrA, associated with fluoroquinolone resistance in Streptococcus pneumoniae. Antimicrob Agents Chemother 1999; 43: 187-189.
80. Munoz-Bellido JL, Alonzo MM, Martinez Andres JA et al. Efflux pump-mediated quinolone resistance in Staphylococcus aureus strains wild type for gyrA, gyrB, grlA, and norA. Antimicrob Agents Chemother 1999; 43: 354-356.
81. Aeschlimann JR, Dresser LD, Kaatz GW, Rybak MJ. Effects of NorA inhibitors on in vitro antibacterial activities and postantibiotic effects of levofloxacin, ciprofloxacin, and norfloxacin in genetically related strains of Staphylococcus aureus. Antimicrob Agents Chemother 1999; 43: 335-340.
82. Miyamae S, Nikaido H, Tanaka Y, Yoshimura F. Active efflux of norfloxacin by Bacteroides fragilis. Antimicrob Agents Chemother 1998; 42: 2119-2121.
83. Mine T, Morita Y, Kataoka A, Mizushima T, Tsuchiya T. Expression in Escherichia coli of a new multidrug efflux pump, MexXY, from Pseudomonas aeruginosa. Antimicrob Agents Chemother 1999; 43: 415-417.
84. Ziha-Zarifi I, Llanes C, Kohler T, Pechere JC, Plesiat P. In vivo emergence of multidrug-resistant mutants of Pseudomonas aeruginosa overexpressing the active efflux system MexA-MexB-OprM. Antimicrob Agents Chemother 1999; 43: 287-291.
85. Martinez-Martinez L, Pascual A, Jacoby GA. Quinolone resistance from a transferable plasmid. Lancet 1998; 351: 797-799.
86. Wang M, Tran JH, Jacoby GA, Zhang Y, Wang F, Hooper DC. Plasmid-mediated quinolone resistance in clinical isolates of Escherichia coli from Shanghai, China. Antimicrob Agents Chemother 2003; 47: 2242-2248.
87. Tran JH, Jacoby GA. Mechanism of plasmid-mediated quinolone resistance. Proc Natl Acad Sci USA 2002; 99: 5638-5642.
88. Tran JH, Jacoby GA, Hooper DC. Interaction of the plasmid-encoded quinolone resistance protein Qnr with Escherichia coli DNA gyrase. Antimicrob Agents Chemother 2005; 49: 118-125.
89. Rodriguez-Martinez JM, Pascual A, Garcia I, Martinez-Martinez L. Detection of the plasmid-mediated quinolone resistance determinant qnr among clinical isolates of Klebsiella pneumoniae producing AmpC-type beta-lactamase. J Antimicrob Chemother 2003; 52: 703-706.
90. Mammeri H, Van De LM, Poirel L, Martinez-Martinez L, Nordmann P. Emergence of plasmid-mediated quinolone resistance in Escherichia coli in Europe. Antimicrob Agents Chemother 2005; 49: 71-76.
91. Cunha BA. Intravenous to oral antibiotic switch therapy. Drugs Today (Barc) 2001; 37: 311-319.
92. Phillips I, King A. Comparative activity of the 4-quinolones. Rev Infect Dis 1988; 10(suppl 1): S70-S76.
93. Roosendaal R, Bakker-Woudenberg IA, van den Berghevan Raffe M, Vink-van den Berg JC, Michel MF. Comparative activities of ciprofloxacin and ceftazidime against Klebsiella pneumoniae in vitro and in experimental pneumonia in leukopenic rats. Antimicrob Agents Chemother 1987; 31: 1809-1815.
94. Chin NX, Neu HC. Post-antibiotic suppressive effect of ciprofloxacin against gram-positive and gram-negative bacteria. Am J Med 1987; 82: 58-62.
95. Drusano GL, Johnson DE, Rosen M, Standiford HC. Pharmacodynamics of a fluoroquinolone antimicrobial agent in a neutropenic rat model of Pseudomonas sepsis. Antimicrob Agents Chemother 1993; 37: 483-490.
96. Mouton JW, Dudley MN, Cars O, Derendorf H, Drusano GL. Standardization of pharmacokinetic/pharmacodynamic (PK/PD) terminology for anti-infective drugs. Int J Antimicrob Agents 2002; 19: 355-358.
97. Peloquin CA, Cumbo TJ, Nix DE, Sands MF, Schentag JJ. Evaluation of intravenous ciprofloxacin in patients with nosocomial lower respiratory tract infections. Impact of plasma concentrations, organism, minimum inhibitory concentration, and clinical condition on bacterial eradication. Arch Intern Med 1989; 149: 2269-2273.
98. Lee BL, Padula AM, Kimbrough RC et al. Infectious complications with respiratory pathogens despite ciprofloxacin therapy. N Engl J Med 1991; 325: 520-521.
99. Nix DE, Sands MF, Peloquin CA et al. Dual individualization of intravenous ciprofloxacin in patients with nosocomial lower respiratory tract infections. Am J Med 1987; 82 352-356.
100. Forrest A, Nix DE, Ballow CH, Goss TF, Birmingham MC, Schentag JJ. Pharmacodynamics of intravenous ciprofloxacin in seriously ill patients. Antimicrob Agents Chemother 1993; 37: 1073-1081.
101. Preston SL, Drusano GL, Berman AL et al. Pharmacodynamics of levofloxacin: a new paradigm for early clinical trials. JAMA 1998; 279: 125-129.
102. Ambrose PG, Bhavnani SM, Owens RC. Clinical pharmacodynamics of quinolones. Infect Dis Clin North Amer 2003; 17: 529-543.
103. Jones RN, Rubino CM, Bhavnani SM, Ambrose PG. Worldwide antimicrobial susceptibility patterns and pharmacodynamic comparisons of gatifloxacin and levofloxacin against Streptococcus pneumoniae: report from the Antimicrobial Resistance Rate Epidemiology Study Team. Antimicrob Agents Chemother 2003; 47: 292-296.
104. Owens RC, Bhavnani SM, Ambrose PG. Assessment of pharmacokinetic-pharmacodynamic target attainment of gemifloxacin against Streptococcus pneumoniae. Diagn Microbiol Infect Dis 2005; 51 45-49.
105. Jacobs MR. Optimisation of antimicrobial therapy using pharmacokinetic and pharmacodynamic parameters. Clin Microbiol Infect 2001; 7: 589-596.
106. Schentag JJ, Meagher AK, Forrest A. Fluoroquinolone AUIC break points and the link to bacterial killing rates. Part 1: In vitro and animal models. Ann Pharmacother 2003; 37: 1287-1298.
107. Klepser ME, Ernst EJ, Petzold CR, Rhomberg P, Doern GV. Comparative bactericidal activities of ciprofloxacin, clinafloxacin, grepafloxacin, levofloxacin, moxifloxacin, and trovafloxacin against Streptococcus pneumoniae in a dynamic in vitro model. Antimicrob Agents Chemother 2001; 45: 673-678.
108. Andes D, Craig WA. Pharmacodynamics of the new fluoroquinolone gatifloxacin in murine thigh and lung infection models. Antimicrob Agents Chemother 2002; 46: 1665-1670.
109. Schentag JJ, Meagher AK, Forrest A. Fluoroquinolone AUIC break points and the link to bacterial killing rates. Part 2: human trials. Ann Pharmacother 2003; 37: 1478-1488.
110. Drusano GL. Pharmacokinetics of the quinolone antimicrobial agents. In: Wolfson JS, Hooper DC, eds. Quinolone antimicrobial agents Washington, DC: American Society for Microbiology, 1989; 71-106.
111. Kays MB, Graff MA. Broth microdilution and E-test for determining fluoroquinolone activity against Streptococcus pneumoniae. Ann Pharmacother 2002; 36: 416-422.
112. Nicolau DP, Mattoes HM, Banevicius M, Xuan D, Nightingale CH. Pharmacodynamics of a novel des-F (6)-quinolone, BMS-284756, against Streptococcus pneumoniae in the thigh infection model. Antimicrob Agents Chemother 2003; 47: 1630-1635.
113. Zeitlinger MA, Sauermann R, Traunmuller F, Georgopoulos A, Muller M, Joukhadar C. Impact of plasma protein binding on antimicrobial activity using time-killing curves. J Antimicrob Chemother 2004; 54: 876-880.
114. Thomas JK, Forrest A, Bhavnani SM et al. Pharmacodynamic evaluation of factors associated with the development of bacterial resistance in acutely ill patients during therapy. Antimicrob Agents Chemother 1998; 42: 521-527.
115. Firsov AA, Zinner SH, Vostrov SN, Portnoy YA, Lubenko IY. AUC/MIC relationships to different endpoints of the antimicrobial effect: multiple-dose in vitro simulations with moxifloxacin and levofloxacin. J Antimicrob Chemother 2002; 50: 533-539.
116. Zinner SH, Lubenko IY, Gilbert D et al. Emergence of resistant Streptococcus pneumoniae in an in vitro dynamic model that simulates moxifloxacin concentrations inside and outside the mutant selection window: related changes in susceptibility, resistance frequency and bacterial killing. J Antimicrob Chemother 2003; 52: 616-622.
117. MacGowan AP, Rogers CA, Holt HA, Bowker KE. Activities of moxifloxacin against, and emergence of resistance in, Streptococcus pneumoniae and Pseudomonas aeruginosa in an in vitro pharmacokinetic model. Antimicrob Agents Chemother 2003; 47: 1088-1095.
118. Gumbo T, Louie A, Deziel MR, Parsons LM, Salfinger M, Drusano GL. Selection of a moxifloxacin dose that suppresses drug resistance in Mycobacterium tuberculosis, by use of an in vitro pharmacodynamic infection model and mathematical modeling. J Infect Dis 2004; 190: 1642-1651.
119. Jumbe N, Louie A, Leary R et al. Application of a mathematical model to prevent in vivo amplification of antibiotic-resistant bacterial populations during therapy. J Clin Invest 2003; 112: 275-285.
120. Drlica K. Refining the fluoroquinolones. ASM News 1999; 65: 410-415.
121. Blondeau JM, Zhao X, Hansen G, Drlica K. Mutant prevention concentrations of fluoroquinolones for clinical isolates of Streptococcus pneumoniae. Antimicrob Agents Chemother 2001; 45: 433-438.
122. Hansen GT, Metzler K, Drlica K, Blondeau JM. Mutant prevention concentration of gemifloxacin for clinical isolates of Streptococcus pneumoniae. Antimicrob Agents Chemother 2003; 47: 440-441.
123. Zhao X, Eisner W, Perl-Rosenthal N, Kreiswirth B, Drlica K. Mutant prevention concentration of garenoxacin (BMS-284756) for ciprofloxacin-susceptible or -resistant Staphylococcus aureus. Antimicrob Agents Chemother 2003; 47: 1023-1027.
124. Firsov AA, Vostrov SN, Lubenko IY, Drlica K, Portnoy YA, Zinner SH. In vitro pharmacodynamic evaluation of the mutant selection window hypothesis using four fluoroquinolones against Staphylococcus aureus. Antimicrob Agents Chemother 2003; 47: 1604-1613.
125. Lu T, Zhao X, Li X, Hansen G, Blondeau J, Drlica K. Effect of chloramphenicol, erythromycin, moxifloxacin, penicillin and tetracycline concentration on the recovery of resistant mutants of Mycobacterium smegmatis and Staphylococcus aureus. J Antimicrob Chemother 2003; 52: 61-64.
126. Randall LP, Cooles SW, Piddock LJ, Woodward MJ. Mutant prevention concentrations of ciprofloxacin and enrofloxacin for Salmonella enterica. J Antimicrob Chemother 2004; 54: 688-691.
127. Linde HJ, Lehn N. Mutant prevention concentration of nalidixic acid, ciprofloxacin, clinafloxacin, levofloxacin, norfloxacin, ofloxacin, sparfloxacin or trovafloxacin for Escherichia coli under different growth conditions. J Antimicrob Chemother 2004; 53: 252-257.
128. Li X, Mariano N, Rahal JJ, Urban CM, Drlica K. Quinolone-resistant Haemophilus influenzae: determination of mutant selection window for ciprofloxacin, garenoxacin, levofloxacin, and moxifloxacin. Antimicrob Agents Chemother 2004; 48: 4460-4462.
129. Zhao X, Drlica K. Restricting the selection of antibiotic-resistant mutants: a general strategy derived from fluoroquinolone studies. Clin Infect Dis 2001; 33(suppl 3): S147-S156.
130. Epstein BJ, Gums JG, Drlica K. The changing face of antibiotic prescribing: the mutant selection window. Ann Pharmacother 2004; 38: 1675-1682.
131. Allen GP, Kaatz GW, Rybak MJ. Activities of mutant prevention concentration-targeted moxifloxacin and levofloxacin against Streptococcus pneumoniae in an in vitro pharmacodynamic model. Antimicrob Agents Chemother 2003; 47: 2606-2614.
132. Smith HJ, Walters M, Hisanaga T, Zhanel GG, Hoban DJ. Mutant prevention concentrations for single-step fluoroquinolone-resistant mutants of wild-type, efflux-positive, or ParC or GyrA mutation-containing Streptococcus pneumoniae isolates. Antimicrob Agents Chemother 2004; 48: 3954-3958.
133. Croisier D, Etienne M, Bergoin E et al. Mutant selection window in levofloxacin and moxifloxacin treatments of experimental pneumococcal pneumonia in a rabbit model of human therapy. Antimicrob Agents Chemother 2004; 48: 1699-1707.
134. Blondeau JM, Hansen G, Metzler K, Hedlin P. The role of PK/PD parameters to avoid selection and increase of resistance: mutant prevention concentration. J Chemother 2004; 16(suppl 3): 1-19.
135. Nightingale CH. Moxifloxacin, a new antibiotic designed to treat community-acquired respiratory tract infections: a review of microbiologic and pharmacokinetic-pharmacodynamic characteristics. Pharmacotherapy 2000; 20: 245-256.
136. Obritsch MD, Fish DN, MacLaren R, Jung R. National surveillance of antimicrobial resistance in Pseudomonas aeruginosa isolates obtained from intensive care unit patients from 1993 to 2002. Antimicrob Agents Chemother 1993; 48: 4606-4610.
137. Astal Z. Susceptibility patterns in Pseudomonas aeruginosa causing nosocomial infections. J Chemother 2004; 16: 264-268.
138. Jang CH, Park SY. Emergence of ciprofloxacin-resistant pseudomonas in chronic suppurative otitis media. Clin Otolaryngol 2004; 29: 321-323.
139. Lau SM, Peng MY, Chang FY. Resistance rates to commonly used antimicrobials among pathogens of both bacteremic and non-bacteremic community-acquired urinary tract infection. J Microbiol Immunol Infect 2004; 37: 185-191.
140. Jung R, Fish DN, Obritsch MD, MacLaren R. Surveillance of multi-drug resistant Pseudomonas aeruginosa in an urban tertiary-care teaching hospital. J Hosp Infect 2004; 57: 105-111.
141. Cermak P, Kolar M, Latal T. Frequency of Gram-negative bacterial pathogens in bloodstream infections and their resistance to antibiotics in the Czech Republic. Int J Antimicrob Agents 2004; 23: 401-404.
142. Unal S, Masterton R, Goossens H. Bacteraemia in Europe - antimicrobial susceptibility data from the MYSTIC surveillance programme. Int J Antimicrob Agents 2004; 23: 155-163.
143. De Vecchi E, Drago L, Nicola L et al. Resistance of Pseudomonas aeruginosa to ciprofloxacin and levofloxacin: 1998-2002. Infez Med 2003; 11: 196-200.
144. Kern WV, Steib-Bauert M, de With K et al. Fluoroquinolone consumption and resistance in haematology-oncology patients: ecological analysis in two university hospitals 1999-2002. J Antimicrob Chemother 2005; 55: 57-60.
145. Polk RE, Johnson CK, McClish D, Wenzel RP, Edmond MB. Predicting hospital rates of fluoroquinolone-resistant Pseudomonas aeruginosa from fluoroquinolone use in US hospitals and their surrounding communities. Clin Infect Dis 2004; 39: 497-503.
146. Meyer E, Jonas D, Schwab F, Gastmeier P, Ruden H, Daschner FD. SARI: surveillance of antibiotic use and bacterial resistance in German intensive care units. Correlation between antibiotic use and the emergence of resistance. Bundesgesundheitsblatt Gesundheitsforschung Gesundheitsschutz 2004; 47: 345-351.
147. Mohr JF, Jones A, Ostrosky-Zeichner L, Wanger A, Tillotson G. Associations between antibiotic use and changes in susceptibility patterns of Pseudomonas aeruginosa in a private, university-affiliated teaching hospital: an 8-year-experience: 1995-2002. Int J Antimicrob Agents 2004; 24: 346-351.
148. Karlowsky JA, Thornsberry C, Jones ME, Sahm DF. Susceptibility of antimicrobial-resistant urinary Escherichia coli isolates to fluoroquinolones and nitrofurantoin. Clin Infect Dis 2003; 36: 183-187.
149. Abelson SK, Osterlund A, Kahlmeter G. Antimicrobial resistance in Escherichia coli in urine samples from children and adults: a 12 year analysis. Acta Paediatr 2004; 93: 487-491.
150. Kahlmeter G, Menday P, Cars O. Non-hospital antimicrobial usage and resistance in community-acquired Escherichia coli urinary tract infection. J Antimicrob Chemother 2003; 52: 1005-1010.
151. Kahlmeter G. Prevalence and antimicrobial susceptibility of pathogens in uncomplicated cystitis in Europe. The ECO.SENS study. Int J Antimicrob Agents 2003; 22(suppl 2): 49-52.
152. Canton R, Morosini M, Enright MC, Morrissey I. Worldwide incidence, molecular epidemiology and mutations implicated in fluoroquinolone-resistant Streptococcus pneumoniae: data from the global PROTEKT surveillance programme. J Antimicrob Chemother 2003; 52: 944-952.
153. Karlowsky JA, Thornsberry C, Jones ME, Evangelista AT, Critchley IA, Sahm DF. Factors associated with relative rates of antimicrobial resistance among Streptococcus pneumoniae in the United States: results from the TRUST Surveillance Program (1998-2002). Clin Infect Dis 2003; 36: 963-970.
154. Jacobs MR, Felmingham D, Appelbaum PC, Gruneberg RN. The Alexander Project 1998-2000: susceptibility of pathogens isolated from community-acquired respiratory tract infection to commonly used antimicrobial agents. J Antimicrob Chemother 2003; 52: 229-246.
155. Chen DK, McGeer A, de Azavedo JC, Low DE. Decreased susceptibility of Streptococcus pneumoniae to fluoroquinolones in Canada. Canadian Bacterial Surveillance Network. N Engl J Med 1999; 341: 233-239.
156. Ho PL, Que TL, Tsang DN, Ng TK, Chow KH, Seto WH. Emergence of fluoroquinolone resistance among multiply resistant strains of Streptococcus pneumoniae in Hong Kong. Antimicrob Agents Chemother 1999; 43: 1310-1313.
157. Ho PL, Tse WS, Tsang KW et al. Risk factors for acquisition of levofloxacin-resistant Streptococcus pneumoniae: a case-control study. Clin Infect Dis 2001; 32: 701-707.
158. Bhavnani SM, Hammel JP, Jones RN, Ambrose PG. Relationship between increased levofloxacin use and decreased susceptibility of Streptococcus pneumoniae in the United States. Diagn Microbiol Infect Dis 2005; 51: 31-37.
159. Davidson R, Cavalcanti R, Brunton JL et al. Resistance to levofloxacin and failure of treatment of pneumococcal pneumonia. N Engl J Med 2002; 346: 747-750.
160. Oteo J, Lazaro E, de Abajo FJ, Baquero F, Campos J. Trends in antimicrobial resistance in 1,968 invasive Streptococcus pneumoniae strains isolated in Spanish hospitals (2001 to 2003): decreasing penicillin resistance in children's isolates. J Clin Microbiol 2004; 42: 5571-5577.
161. Pletz MW, McGee L, Jorgensen J et al. Levofloxacin-resistant invasive Streptococcus pneumoniae in the United States: evidence for clonal spread and the impact of conjugate pneumococcal vaccine. Antimicrob Agents Chemother 2004; 48: 3491-3497.
162. Yokota S, Sato K, Yoshida S, Fujii N. Molecular epidemiology of fluoroquinolone-resistant Streptococcus pneumoniae in Japan. Kansenshogaku Zasshi 2004; 78: 428-434.
163. Klugman KP. The role of clonality in the global spread of fluoroquinolone-resistant bacteria. Clin Infect Dis 2003; 36: 783-785.
164. Blumberg HM, Rimland D, Carroll DJ, Terry P, Wachsmuth IK. Rapid development of ciprofloxacin resistance in methicillin-susceptible and -resistant Staphylococcus aureus. J Infect Dis 1991; 163: 1279-1285.
165. Andersson DI. Persistence of antibiotic resistant bacteria. Curr Opin Microbiol 2003; 6: 452-456.
166. Luo N, Pereira S, Sahin O et al. Enhanced in vivo fitness of fluoroquinolone-resistant Campylobacter jejuni in the absence of antibiotic selection pressure. Proc Natl Acad Sci USA 2005; 102: 541-546.
167. Bastida T, Perez-Vazquez M, Campos J et al. Levofloxacin treatment failure in Haemophilus influenzae pneumonia. Emerg Infect Dis 2003; 9: 1475-1478.
168. Low DE. Quinolone resistance among pneumococci: therapeutic and diagnostic implications. Clin Infect Dis 2004; 38(suppl 4): S357-S362.
169. Capitano B, Mattoes HM, Shore E et al. Steady-state intrapulmonary concentrations of moxifloxacin, levofloxacin, and azithromycin in older adults. Chest 2004; 125: 965-973.
170. O'Donnell JA, Gelone SP. The newer fluoroquinolones. Infect Dis Clin North Am 2004; 18: 691-716.
171. Wagenlehner FM, Naber KG. Fluoroquinolone antimicrobial agents in the treatment of prostatitis and recurrent urinary tract infections in men. Curr Infect Dis Rep 2005; 7: 9-16.
172. Cottagnoud P, Tauber MG. Fluoroquinolones in the treatment of meningitis. Curr Infect Dis Rep 2003; 5: 329-336.
173. Pascual A, Garcia I, Ballesta S, Perea EJ. Uptake and intracellular activity of moxifloxacin in human neutrophils and tissue-cultured epithelial cells. Antimicrob Agents Chemother 1999; 43: 12-15.
174. Carlier MB, Scorneaux B, Zenebergh A, Desnottes JF, Tulkens PM. Cellular uptake, localization and activity of fluoroquinolones in uninfected and infected macrophages. J Antimicrob Chemother 1990; 26(suppl B): 27-39.
175. Walters JD, Zhang F, Nakkula RJ. Mechanisms of fluoroquinolone transport by human neutrophils. Antimicrob Agents Chemother 1999; 43: 2710-2715.
176. Bounds SJ, Nakkula R, Walters JD. Fluoroquinolone transport by human monocytes: characterization and comparison to other cells of myeloid lineage. Antimicrob Agents Chemother 2000; 44: 2609-2614.
177. Seral C, Carryn S, Tulkens PM, Van Bambeke F. Influence of P-glycoprotein and MRP efflux pump inhibitors on the intracellular activity of azithromycin and ciprofloxacin in macrophages infected by Listeria monocytogenes or Staphylococcus aureus. J Antimicrob Chemother 2003; 51: 1167-1173.
178. Hall IH, Schwab UE, Ward ES, Ives T. Disposition and intracellular levels of moxifloxacin in human THP-1 monocytes in unstimulated and stimulated conditions. Int J Antimicrob Agents 2003; 22: 579-587.
179. Carryn S, Chanteux H, Seral C, Mingeot-Leclercq MP, Van Bambeke F, Tulkens PM. Intracellular pharmacodynamics of antibiotics. Infect Dis Clin North Amer 2003; 17: 615-634.
180. Carryn S, Van Bambeke F, Mingeot-Leclercq MP, Tulkens PM. Comparative intracellular (THP-1 macrophage) and extracellular activities of beta-lactams, azithromycin, gentamicin, and fluoroquinolones against Listeria monocytogenes at clinically relevant concentrations. Antimicrob Agents Chemother 2002; 46: 2095-2103.
181. Chang HR, Vladoianu IR, Pechere JC. Effects of ampicillin, ceftriaxone, chloramphenicol, pefloxacin and trimethoprim-sulphamethoxazole on Salmonella typhi within human monocyte-derived macrophages. J Antimicrob Chemother 1990; 26 689-694.
182. Jonas D, Engels I, Friedhoff C, Spitzmuller B, Daschner FD, Frank U. Efficacy of moxifloxacin, trovafloxacin, clinafloxacin and levofloxacin against intracellular Legionella pneumophila. J Antimicrob Chemother 2001; 47: 147-152.
183. Borsum T, Dannevig L, Storvold G, Melby K. Chlamydia trachomatis: in vitro susceptibility of genital and ocular isolates to some quinolones, amoxicillin and azithromycin. Chemotherapy 1990; 36: 407-415.
184. Fenelon LE, Mumtaz G, Ridgway GL. The in-vitro antibiotic susceptibility of Chlamydia pneumoniae. J Antimicrob Chemother 1990; 26: 763-767.
185. Sato K, Tomioka H, Sano C et al. Comparative antimicrobial activities of gatifloxacin, sitafloxacin and levofloxacin against Mycobacterium tuberculosis replicating within Mono Mac 6 human macrophage and A-549 type II alveolar cell lines. J Antimicrob Chemother 2003; 52: 199-203.
186. Seral C, Van Bambeke F, Tulkens PM. Quantitative analysis of gentamicin, azithromycin, telithromycin, ciprofloxacin, moxifloxacin, and oritavancin (LY333328) activities against intracellular Staphylococcus aureus in mouse J774 macrophages. Antimicrob Agents Chemother 2003; 47: 2283-2292.
187. Ahren IL, Karlsson E, Forsgren A, Riesbeck K. Comparison of the antibacterial activities of ampicillin, ciprofloxacin, clarithromycin, telithromycin and quinupristin/dalfopristin against intracellular non-typeable Haemophilus influenzae. J Antimicrob Chemother 2002; 50: 903-906.
188. Nichterlein T, Bornitz F, Kretschmar M, Hof H. Successful treatment of murine listeriosis and salmonellosis with levofloxacin. J Chemother 1998; 10: 313-319.
189. Edelstein PH, Shinzato T, Edelstein MA. BMS-284756 (T-3811ME) a new fluoroquinolone: in vitro activity against Legionella, efficacy in a guinea pig model of L. pneumophila pneumonia and pharmacokinetics in guinea pigs. J Antimicrob Chemother 2001; 48 667-675.
190. Yoshimatsu T, Nuermberger E, Tyagi S, Chaisson R, Bishai W, Grosset J. Bactericidal activity of increasing daily and weekly doses of moxifloxacin in murine tuberculosis. Antimicrob Agents Chemother 2002; 46: 1875-1879.
191. Nakata K, Maeda H, Fujii A, Arakawa S, Umezu K, Kamidono S. In vitro and in vivo activities of sparfloxacin, other quinolones, and tetracyclines against Chlamydia trachomatis. Antimicrob Agents Chemother 1992; 36: 188-190.
192. Miyashita N, Niki Y, Kishimoto T, Nakajima M, Matsushima T. In vitro and in vivo activities of AM-1155, a new fluoroquinolone, against Chlamydia spp. Antimicrob Agents Chemother 1997; 41: 1331-1334.
193. Dunbar LM, Khashab MM, Kahn JB, Zadeikis N, Xiang JX, Tennenberg AM. Efficacy of 750-mg, 5-day levofloxacin in the treatment of community-acquired pneumonia caused by atypical pathogens. Curr Med Res Opin 2004; 20: 555-563.
194. Santos J, Aguilar L, Garcia-Mendez E et al. Clinical characteristics and response to newer quinolones in Legionella pneumonia: a report of 28 cases. J Chemother 2003; 15: 461-465.
195. Yu VL, Greenberg RN, Zadeikis N et al. Levofloxacin efficacy in the treatment of community-acquired legionellosis. Chest 2004; 125: 2135-2139.
196. Gosling RD, Uiso LO, Sam NE et al. The bactericidal activity of moxifloxacin in patients with pulmonary tuberculosis. Am J Respir Crit Care Med 2003; 168: 1342-1345.
197. Valerio G, Bracciale P, Manisco V, Quitadamo M, Legari G, Bellanova S. Long-term tolerance and effectiveness of moxifloxacin therapy for tuberculosis: preliminary results. J Chemother 2003; 15: 66-70.
198. Yew WW, Chan CK, Leung CC et al. Comparative roles of levofloxacin and ofloxacin in the treatment of multidrug-resistant tuberculosis: preliminary results of a retrospective study from Hong Kong. Chest 2003; 124: 1476-1481.
199. Van Bambeke F, Balzi E, Tulkens PM. Antibiotic efflux pumps. Biochem Pharmacol 2000; 60: 457-470.
200. Sasabe H, Kato Y, Suzuki T, Itose M, Miyamoto G, Sugiyama Y. Differential involvement of multidrug resistance-associated protein 1 and p-glycoprotein in tissue distribution and excretion of grepafloxacin in mice. J Pharmacol Exp Ther 2004; 310: 648-655.
201. Foote EF, Halstenson CE. Effects of probenecid and cimeticline on renal disposition of ofloxacin in rats. Antimicrob Agents Chemother 1998; 42: 456-458.
202. Ito T, Yano I, Tanaka K, Inui KI. Transport of quinolone antibacterial drugs by human P-glycoprotein expressed in a kidney epithelial cell line, LLC-PK1. J Pharmacol Exp Ther 1997; 282 955-960.
203. Sasabe H, Terasaki T, Tsuji A, Sugiyama Y. Carrier-mediated hepatic uptake of quinolone antibiotics in the rat. J Pharmacol Exp Ther 1997; 282: 162-171.
204. Sasabe H, Tsuji A, Sugiyama Y. Carrier-mediated mechanism for the biliary excretion of the quinolone antibiotic grepafloxacin and its glucuronide in rats. J Pharmacol Exp Ther 1998; 284: 1033-1039.
205. De Sarro A, Cecchetti V, Fravolini V, Naccari F, Tabarrini O, De Sarro G. Effects of novel 6-desfluoroquinolones and classic quinolones on pentylenetetrazole-induced seizures in mice. Antimicrob Agents Chemother 1999; 43: 1729-1736.
206. Ooie T, Terasaki T, Suzuki H, Sugiyama Y. Kinetic evidence for active efflux transport across the blood-brain barrier of quinolone antibiotics. J Pharmacol Exp Ther 1997; 283: 293-304.
207. Recanatini M, Poluzzi E, Masetti M, Cavalli A, De Ponti F. QT prolongation through hERG K (+) channel blockade: current knowledge and strategies for the early prediction during drug development. Med Res Rev 2005; 25: 133-166.
208. Blum MD, Graham DJ, McCloskey CA. Temafloxacin syndrome: review of 95 cases. Clin Infect Dis 1994; 18: 946-950.
209. Chen HJ, Bloch KJ, Maclean JA. Acute eosinophilic hepatitis from trovafloxacin. N Engl J Med 2000; 342: 359-360.
210. Ball P, Stahlmann R, Kubin R, Choudhri S, Owens R. Safety profile of oral and intravenous moxifloxacin: cumulative data from clinical trials and postmarketing studies. Clin Ther 2004; 26 940-950.
211. Temime L, Boelle PY, Courvalin P, Guillemot D. Bacterial resistance to penicillin G by decreased affinity of penicillin-binding proteins: a mathematical model. Emerg Infect Dis 2003; 9: 411-417.
212. Lautenbach E, Strom BL, Nachamkin I et al. Longitudinal trends in fluoroquinolone resistance among Enterobacteriaceae isolates from inpatients and outpatients, 1989-2000: differences in the emergence and epidemiology of resistance across organisms. Clin Infect Dis 2004; 38: 655-662.
213. Chaniotaki S, Giakouppi P, Tzouvelekis LS et al. Quinolone resistance among Escherichia coli strains from community-acquired urinary tract infections in Greece. Clin Microbiol Infect 2004; 10: 75-78.
214. Carbon C, Isturiz R. Narrow versus broad spectrum antibacterials: factors in the selection of pneumococcal resistance to beta-lactams. Drugs 2002; 62: 1289-1294.
215. Carbon C, Cars O, Christiansen K. Moving from recommendation to implementation and audit: part 1. Current recommendations and programs: a critical commentary. Clin Microbiol Infect 2002; 8 suppl 2): 92-106.
216. Christiansen K, Carbon C, Cars O. Moving from recommendation to implementation and audit: part 2. Review of interventions and audit. Clin Microbial Infect 2002; 8(suppl 2): 107-128.
217. Appelbaum PC, Gillespie SH, Burley CJ, Tillotson GS. Antimicrobial selection for community-acquired lower respiratory tract infections in the 21st century: a review of gemifloxacin. Int J Antimicrob Agents 2004; 23: 533-546.
218. Halpern MT, Palmer CS, Zodet M, Kirsch J. Cost-effectiveness of gemifloxacin: results from the GLOBE study. Am J Health Syst Pharm 2002; 59: 1357-1365.
219. Madan AK. Use of ciprofloxacin in the treatment of hospitalized patients with intra-abdominal infections. Clin Ther 2004; 26: 1564-1577.
220. Drummond MF, Becker DL, Hux M et al. An economic evaluation of sequential i.v./po moxifloxacin therapy compared to i.v./po co-amoxiclav with or without clarithromycin in the treatment of community-acquired pneumonia. Chest 2003; 124: 526-535.
221. Fischer MA, Solomon DH, Teich JM, Avorn J. Conversion from intravenous to oral medications: assessment of a computerized intervention for hospitalized patients. Arch Intern Med 2003; 163: 2585-2589.
222. Kuti JL, Le TN, Nightingale CH, Nicolau DP, Quintiliani R. Pharmacoeconomics of a pharmacist-managed program for automatically converting levofloxacin route from i.v. to oral. Am J Health Syst Pharm 2002; 59: 2209-2215.
223. Pablos AI, Escobar I, Albinana S, Serrano O, Ferrari JM, de Tejada AH. Evaluation of an antibiotic intravenous to oral sequential therapy program. Pharmacoepidemiol Drug Safety 2005; 14: 53-59.
224. Nickel JC. Management of urinary tract infections: historical perspective and current strategies: Part 2 - Modern management. J Urol 2005; 173: 27-32.
225. Louie TJ. Ciprofloxacin: an oral quinolone for the treatment of infections with gram-negative pathogens. Committee on Antimicrobial Agents. Canadian Infectious Disease Society. Can Med Assoc J 1994; 150: 669-676.
226. File TM, Garau J, Blasi F et al. Guidelines for empiric antimicrobial prescribing in community-acquired pneumonia. Chest 2004; 125: 1888-1901.
227. Martinez FJ. Monotherapy versus dual therapy for community-acquired pneumonia in hospitalized patients. Clin Infect Dis 2004; 38(suppl 4): S328-S340.
228. Finch R, Schurmann D, Collins O et al. Randomized controlled trial of sequential intravenous (i.v.) and oral moxifloxacin compared with sequential i.v. and oral co-amoxiclav with or without clarithromycin in patients with community-acquired pneumonia requiring initial parenteral treatment. Antimicrob Agents Chemother 2002; 46: 1746-1754.
229. Desenclos JC, Guillemot D. Consequences of bacterial resistance to antimicrobial agents. Emerg Infect Dis 2004; 10 759-760.
230. Hecht DW. Prevalence of antibiotic resistance in anaerobic bacteria: worrisome developments. Clin Infect Dis 2004; 39: 92-97.
231. Ackermann G, Tang-Feldman YJ, Schaumann R et al. Antecedent use of fluoroquinolones is associated with resistance to moxifloxacin in Clostridium difficile. Clin Microbiol Infect 2003; 9: 526-530.
232. Ricci V, Peterson ML, Rotschafer JC, Wexler H, Piddock LJ. Role of topoisomerase mutations and efflux in fluoroquinolone resistance of Bacteroides fragilis clinical isolates and laboratory mutants. Antimicrob Agents Chemother 2004; 48: 1344-1346.
233. Scheld WM. Maintaining fluoroquinolone class efficacy: review of influencing factors. Emerg Infect Dis 2003; 9: 1-9.
234. Hooper DC. Minimizing potential resistance: the molecular view - a comment on Courvalin and Trieu-Cuot. Clin Infect Dis 2001; 33(suppl 3): S157-S160.
235. Courvalin P, Trieu-Cuot P. Minimizing potential resistance: the molecular view. Clin Infect Dis 2001; 33(suppl 3): S138-S146.
236. Kishii R, Takei M, Fukuda H, Hayashi K, Hosaka M. Contribution of the 8-methoxy group to the activity of gatifloxacin against type II topoisomerases of Streptococcus pneumoniae. Antimicrob Agents Chemother 2003; 47: 77-81.
237. Takei M, Fukuda H, Kishii R, Hosaka M. Target preference of 15 quinolones against Staphylococcus aureus, based on antibacterial activities and target inhibition. Antimicrob Agents Chemother 2001; 45: 3544-3547.
238. Akasaka T, Onodera Y, Tanaka M, Sato K. Cloning, expression, and enzymatic characterization of Pseudomonas aeruginosa topoisomerase IV. Antimicrob Agents Chemother 1999; 43: 530-536.
239. Morrissey I, George J. Activities of fluoroquinolones against Streptococcus pneumoniae type II topoisomerases purified as recombinant proteins. Antimicrob Agents Chemother 1999; 43: 2579-2585.
240. Yague G, Morris JE, Pan XS, Gould KA, Fisher LM. Cleavable-complex formation by wild-type and quinolone-resistant Streptococcus pneumoniae type II topoisomerases mediated by gemifloxacin and other fluoroquinolones. Antimicrob Agents Chemother 2002; 46: 413-419.
241. Kahlmeter G, Brown DF, Goldstein FW et al. European harmonization of MIC breakpoints for antimicrobial susceptibility testing of bacteria. J Antimicrob Chemother 2003; 52: 145-148.
242. Decousser JW, Allouch PY, Courvalin P, Leclercq R. In vitro activity of moxifloxacin against recent community-acquired respiratory tract pathogens isolated in France: a national survey. Int J Antimicrob Agents 2002; 20: 186-195.
243. Ball P, Mandell L, Niki Y, Tillotson G. Comparative tolerability of the newer fluoroquinolone antibacterials. Drug Safety 1999; 21: 407-421.
244. Ferguson J. Phototoxicity due to fluoroquinolones. In: Hooper DC, Rubinstein E, eds. Quinolone antimicrobial agents. Washington, DC: ASM Press, 2003; 451-460.
245. Burdge DR, Nakielna EM, Rabin HR. Photosensitivity associated with ciprofloxacin use in adult patients with cystic fibrosis. Antimicrob Agents Chemother 1995; 39: 793.
246. Anonymous. Gemifloxacin. Factive, LB 20304, SB 265805. Drugs Res Dev 2002; 3: 258-270.
247. Pertuiset E, Lenoir G, Jehanne M, Douchain F, Guillot M, Menkes CJ. Joint tolerance of pefloxacin and ofloxacin in children and adolescents with cystic fibrosis. Rev Rhum Mal Osteoartic 1989; 56: 735-740.
248. Jick S. Ciprofloxacin safety in a pediatric population. Pediatr Infect Dis J 1997; 16: 130-133.
249. Saint F, Salomon L, de la Cicco ATA, Chopin D, Abbou CC. Tendinopathy associated with fluoroquinolones: individuals at risk, incriminated physiopathologic mechanisms, therapeutic management. Prog Urol 2001; 11: 1331-1334.
250. Pierfitte C, Royer RJ. Tendon disorders with fluoroquinolones. Therapie 1996; 51: 419-420.
251. Kahn MF. Achilles tendinitis and ruptures. Br J Sports Med 1998; 32: 266.
252. Khaliq Y, Zhanel GG. Fluoroquinolone-associated tendinopathy: a critical review of the literature. Clin Infect Dis 2003; 36 1404-1410.
253. Stahlmann R. Effects on connective tissue structures. In: Hooper DC Rubinstein E, eds. Quinolone antimicrobial agents. Washington, DC: ASM Press, 2003; 441-449.
254. Stahlmann R, Lode H. Fluoroquinolones in the elderly: safety considerations. Drugs Aging 2003; 20: 289-302.
255. Norrby R. Central nervous system toxicity. In: Hooper DC, Rubinstein E, eds. Quinolone antimicrobial agents. Washington, DC: ASM Press, 2003; 461-465.
256. Stahlmann R. Clinical toxicological aspects of fluoroquinolones. Toxicol Lett 2002; 127: 269-277.
257. Bowie WR, Willetts V, Jewesson PJ. Adverse reactions in a dose-ranging study with a new long-acting fluoroquinolone, fleroxacin. Antimicrob Agents Chemother 1989; 33: 1778-1782.
258. Yap YG, Camm AJ. QT prolongation with quinolone antibacterial agents. In: Hooper DC, Rubinstein E, eds. Quinolone antibacterial agents. Washington, DC: ASM Press, 2003; 421-440.
259. Hurst M, Lamb HM, Scott LJ, Figgitt DP. Levofloxacin: an updated review of its use in the treatment of bacterial infections. Drugs 2002; 62: 2127-2167.
260. Ball P, Mandell L, Patou G, Dankner W, Tillotson G. A new respiratory fluoroquinolone, oral gemifloxacin: a safety profile in context. Int J Antimicrob Agents 2004; 23: 421-429.
261. Lode H, Rubinstein E. Adverse effects. In: Hooper DC, Rubinstein E, eds. Quinolone antimicrobial agents. Washington, DC: ASM Press, 2003; 407-419.
262. Bertino J, Fish D. The safety profile of the fluoroquinolones. Clin Ther 2000; 22: 798-817.
263. Friedrich LV, Dougherty R. Fatal hypoglycemia associated with levofloxacin. Pharmacotherapy 2004; 24: 1807-1812.
264. Menzies DJ, Dorsainvil PA, Cunha BA, Johnson DH. Severe and persistent hypoglycemia due to gatifloxacin interaction with oral hypoglycemic agents. Am J Med 2002; 113: 232-234.
265. Amankwa K, Krishnan SC, Tisdale JE. Torsades de pointes associated with fluoroquinolones: importance of concomitant risk factors. Clin Pharmacol Ther 2004; 75: 242-247.
266. Corrao G, Botteri E, Bagnardi V et al. Generating signals of drug-adverse effects from prescription databases and application to the risk of arrhythmia associated with antibacterials. Pharmacoepidemiol Drug Safety 2005; 14: 31-40.
267. Nicolle LE. Quinolones in the aged. Drugs 1999; 58 suppl 2): 49-51.
268. Gendrel D, Moulin F. Fluoroquinolones in paediatrics. Paediatr Drugs 2001; 3: 365-377.
269. Zhanel GG, Noreddin AM. Pharmacokinetics and pharmacodynamics of the new fluoroquinolones: focus on respiratory infections. Curr Opin Pharmacol 2001; 1: 459-463.
270. Vogel F. Intravenous/oral sequential therapy in patients hospitalised with community-acquired pneumonia: which patients, when and what agents? Drugs 2002; 62: 309-317.
271. Ball P, Mandell L. Treatment of community-acquired infections. In: Hooper DC, Rubinstein E, eds. Quinolone antimicrobial agents. Washington, DC: ASM Press, 2003; 227-243.
272. Rubinstein E. Fluoroquinolones in intensive care unit infections. In: Hooper DC, Rubinstein E, eds. Quinolone antimicrobial agents. Washington, DC: ASM Press, 2003; 337-342.
273. Karchmer AW. Fluoroquinolone treatment of skin and skin structure infections. Drugs 1999; 58(suppl 2): 82-84.
274. Karchmer AW. Treatment of skin and soft tissue infections. In: Hooper DC, Rubinstein E, eds. Quinolone antimicrobial agents. Washington, DC: ASM Press, 2003; 311-321.
275. Bernard L, Waldvogel F, Lew D. Treatment of osteomyelitis and septic arthritis. In: Hooper DC, Rubinstein E, eds. Quinolone antimicrobial agents. Washington, DC: ASM Press, 2003; 251-258.
276. Solomkin JS. Treatment of intra-abdominal infections. In: Hooper DC, Rubinstein E, eds. Quinolone antimicrobial agents. Washington, DC: ASM Press, 2003; 217-226.
277. Bennish ML. Treatment and prophylaxis of gastro-enteritis. In: Hooper DC, Rubinstein E, eds. Quinolone antimicrobial agents. Washington, DC: ASM Press, 2003; 193-216.
278. Ronald A. The quinolones and renal infection. Drugs 1999; 58(suppl 2): 96-98.
279. Wagenlehner FM, Naber KG. Fluoroquinolone antimicrobial agents in the treatment of prostatitis and recurrent urinary tract infections in men. Curr Urol Rep 2004; 5: 309-316.
280. Skerk V, Schonwald S, Krhen I et al. Comparative analysis of azithromycin and ciprofloxacin in the treatment of chronic prostatitis caused by Chlamydia trachomatis. Int J Antimicrob Agents 2003; 21: 457-462.
281. Dan M. The use of fluoroquinolones in gonorrhoea: the increasing problem of resistance. Expert Opin Pharmacother 2004; 5: 829-854.
282. Tunkel AR, Scheld WM. Treatment of bacterial meningitis and other central nervous system infections. In: Hooper DC, Rubinstein E, eds. Quinolone antimicrobial agents. Washington, DC: ASM Press, 2003; 275-289.
283. Lesher GY, Gruett MD. Substituted 4-oxo-1,8-naphthyridines and intermediates. Belgian patent no. BE 612258. Assigned to: Sterling Drug Inc. 1962.
284. Deitz WH, Bailey JH, Froelich EJ. In vitro antibacterial properties of nalidixic acid, a new drug active against Gram-negative organisms. Antimicrob Agents Chemother 1963; 161: 583-587.
285. Anonymous. Substituted quinolinecarboxy acid. Belgian patent no. BE 870917. Assigned to: Kyorin Pharmaceutical Co. Ltd Japan. 1979.
286. Ito A, Hirai K, Inoue M et al. In vitro antibacterial activity of AM-715, a new nalidixic acid analog. Antimicrob Agents Chemother 1980; 17: 103-108.
287. Khan MY, Siddiqui Y, Gruninger RP. Comparative in vitro activity of Mk-0366 and other selected oral antimicrobial agents against Neisseria gonorrhoeae. Antimicrob Agents Chemother 1981; 20: 265-266.
288. Goueffon Y, Montay G, Roquet F, Pesson M. A new synthetic antibacterial: 1-ethyl-6-fluoro-7-(4- methyl-1-piperazinyl)-4-oxo-1, 4-dihydroquinolin- 3-carboxylic acid (1589 R.B.). C R Seances Acad Sci III 1981; 292: 37-40.
289. Pesson M. 7-Dialkylamino-6- halo-4-oxo-1,4-dihydro -3-quinolinecarboxylic acids. German patent no. DE 2840910197919790405. 1979.
290. Hirose T, Okezaki E, Kato H, Ito Y, Inoue M, Mitsuhashi S. In vitro and in vivo activity of NY-198, a new difluorinated quinolone. Antimicrob Agents Chemother 1987; 31: 854-859.
291. Itoh Y, Kato H, Ogawa N, Koshinaka E, Suzuki T, Yagi N. 6-Fluoro-1,4-dihydro-4-oxo-7-(substituted piperazinyl) quinoline-3-carboxylic acid derivatives. German patent no. DE 3433924. Assigned to: Hokuriku Pharmaceutical Co. Ltd, Japan. 1985.
292. Bauernfeind A, Petermuller C. In vitro activity of ciprofloxacin, norfloxacin and nalidixic acid. Eur J Clin Microbiol 1983; 2: 111-115.
293. Wise R, Andrews JM, Edwards LJ. In vitro activity of Bay 09867, a new quinoline derivative, compared with those of other antimicrobial agents. Antimicrob Agents Chemother 1983; 23: 559-564.
294. Grohe K, Zeiler HJ, Metzger K. 1-Cyclopropyl-6-fluoro-1,4-dihydro-4-oxo-7- piperazinoquinoline-3-carboxylic acids and an antibacterial agent containing them. German patent no. DE 3142854. Assigned to: Bayer A.-G. Fed. Report Ger. 1983.
295. Sato K, Matsuura Y, Inoue M et al. In vitro and in vivo activity of DL-8280, a new oxazine derivative. Antimicrob Agents Chemother 1982; 22: 548-553.
296. Hayakawa I, Tanaka Y, Hiramitsu T. Benzoxazine derivatives. Eur. Pat. Appl. patent no. EP 47005. Assigned to: Daiichi Seiyaku Co. Ltd Japan. 1982.
297. Hayakawa I, Atarashi S, Yokohama S et al. Optically active (S)-(-)-pyridobenzoxazinecarboxylate derivatives, their intermediates, use as antimicrobials. Eur. Pat. Appl. patent no. EP 206283. Assigned to: Daiichi Seiyaku Co. Ltd, Japan. 1986.
298. Hayakawa I, Atarashi S, Yokohama S, Imamura M, Sakano K, Furukawa M. Synthesis and antibacterial activities of optically active ofloxacin. Antimicrob Agents Chemother 1986; 29: 163-164.
299. Nakamura S, Minami A, Nakata K et al. In vitro and in vivo antibacterial activities of AT-4140, a new broad-spectrum quinolone. Antimicrob Agents Chemother 1989; 33: 1167-1173.
300. Matsumoto J, Miyamoto T, Egawa H, Nakamura S. Preparation of piperazinylquinolonecarboxylates as bactericides. Eur. Pat. Appl. patent no. EP 221463. Assigned to: Dainippon Pharmaceutical Co. Ltd, Japan. 1987.
301. Imada T, Miyazaki S, Nishida M, Yamaguchi K, Goto S. In vitro and in vivo antibacterial activities of a new quinolone, OPC-17116. Antimicrob Agents Chemother 1992; 36: 573-579.
302. Ueda H, Miyamoto H, Yamashita H, Tone H. Preparation of quinolinonecarboxylates as bactericides. Eur. Pat. Appl. patent no. EP 287951. Assigned to: Otsuka Pharmaceutical Co. Ltd, Japan. 1988.
303. Hosaka M, Yasue T, Fukuda H, Tomizawa H, Aoyama H, Hirai K. In vitro and in vivo antibacterial activities of AM-1155, a new 6-fluoro-8-methoxy quinolone. Antimicrob Agents Chemother 1992; 36: 2108-2117.
304. Iwata M, Kimura T, Fujiwara Y, Katsube T. Preparation of alkoxyfluoroquinolonecarboxylic acid derivatives as medical bactericides. Eur. Pat. Appl. patent no. EP 241206. Assigned to: Sankyo Co. Ltd, Ube Industries Ltd, Japan. 1987.
305. Gooding BB, Jones RN. In vitro antimicrobial activity of CP-99,219, a novel azabicyclo-naphthyridone. Antimicrob Agents Chemother 1993; 37: 349-353.
306. Brighty KE. Preparation of azabicycloalkylquinolones and -naphthyridinones as antibacterials. US patent no. US 5164402 (abandoned). Assigned to: Pfizer Inc., USA. 1992.
307. Dalhoff A, Petersen U, Endermann R. In vitro activity of BAY 12-8039, a new 8-methoxyquinolone. Chemotherapy 1996; 42: 410-425.
308. Petersen U, Krebs A, Schenke T et al. Preparation of (diazabicyclononyl) quinolones and related compounds as antibacterials. Eur. Pat. Appl. patent nno. EP 550903. Assigned to: Bayer A.-G., Germany. 1993.
309. Oh JI, Paek KS, Ahn MJ et al. In vitro and in vivo evaluations of LB20304, a new fluoronaphthyridone. Antimicrob Agents Chemother 1996; 40: 1564-1568.
310. Kwak JH, Jeong YN, Oh JI. Preparation of novel 7-[(4-aminomethyl-3- alkoxyimino)pyrrolidin-1- yl]quinoline-3-carboxylic acid derivatives as antibacterial agents. Eur. Pat. Appl. patent no. EP 688772. Assigned to: LG Chemical Ltd, South Korea. 1995.
311. Takahata M, Mitsuyama J, Yamashiro Y et al. In vitro and in vivo antimicrobial activities of T-3811ME, a novel des-F(6)-quinolone. Antimicrob Agents Chemother 1999; 43: 1077-1084.
312. Todo Y, Hayashi K, Takahata M, Watanabe Y, Narita H. Preparation of quinolonecarboxylic acid derivatives as antibiotics. PCT Int. Appl.patent no. WO 9729102. Assigned to: Toyama Chemical Co. Ltd, Japan. 1997.